

Application Number: 10/602,456
Balschmidt et al.
Filed: June 23, 2003
Attorney Docket No.: 6460.200-US
Via Facsimile No.: 571-273-8300

AMENDMENTS TO THE CLAIMS

CLAIM LISTING

1. (Currently amended) A pharmaceutical composition comprising ~~which comprises~~ a peptide and one or more isotonicity agents, wherein at least one of the isotonicity agents is dimethyl sulfone, wherein the concentration of dimethyl sulfone is from 40 to 400 mM, wherein the peptide is selected from human growth hormone, GLP-1, GLP-2, insulin, Factor VIIa, Factor VIII, erythropoietin (EPO), glucagon, interleukin-2 (IL-2), interferon- α , and interferon- β , an analog of the peptide, a derivative of the peptide, or derivative of the analog of the peptide or an analogue thereof, or derivative thereof, or derivative of an analogue thereof, and wherein the pharmaceutical composition is administered parenterally to a subject in need thereof for parenteral administration.

2. (Cancelled)

3. (Previously presented) A pharmaceutical composition according to claim 1, wherein the concentration of dimethyl sulfone is from 125 to 350 mM.

4. (Original) A pharmaceutical composition according to claim 1, wherein the composition is a solution.

5. (Original) A pharmaceutical composition according to claim 1, wherein the composition is a suspension.

6. (Currently amended) A pharmaceutical composition according to claim 1, ~~which is suitable for administration wherein the pharmaceutical composition is administered by injection or infusion to a subject in need thereof by injection or infusion~~.

Application Number: 10/602,456
Balschmidt et al.
Filed: June 23, 2003
Attorney Docket No.: 6460.200-US
Via Facsimile No.: 571-273-8300

7. (Currently amended) A pharmaceutical composition according to claim 6, ~~which is suitable for wherein the pharmaceutical composition is administered subcutaneously to a subject in need thereof subcutaneous administration.~~

8. (Currently amended) A pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is administered intramuscularly to a subject in need thereof ~~which is suitable for intramuscular administration.~~

9. (Currently amended) A pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is administered intravenously to a subject in need thereof ~~which is suitable for intravenous administration.~~

10. (Currently amended) A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered pulmonaly to a subject in need thereof ~~which is suitable for pulmonal administration.~~

11. (Currently ameded) A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered ophthalmically or topically to a subject in need thereof ~~which is suitable for ophthalmic administration or topical administration.~~

12. (Cancelled)

13. (Previously presented) A pharmaceutical composition according to claim 1, wherein the peptide is selected from human insulin, a derivative of human insulin, an analogue of human insulin, or a derivative of an analogue of human insulin.

14. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is human insulin.

Application Number: 10/602,456
Balschmidt et al.
Filed: June 23, 2003
Attorney Docket No.: 6460.200-US
Via Facsimile No.: 571-273-8300

15. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Asp(B28)-human insulin.

16. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B28) Pro(B29)-human insulin.

17. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B3) Glu(B29)-human insulin.

18. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is N^εB29-tetradecanoyl des (B30)-human insulin.

19. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Gly(A21) Arg(B31) Arg(B32)-human insulin.

20. (Previously presented) A pharmaceutical composition according to claim 13, wherein the peptide is N^εB29-lithocholoyl-γ-glutamyl des (B30)-human insulin.

21. (Previously presented) A pharmaceutical composition according to claim 1, wherein the peptide is Gly(8)-human GLP-1.

22. (Previously presented) A pharmaceutical composition according to claim 1, wherein the peptide is Arg(34), N-ε-(γ-Glu(N-α-hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.

23. (Previously presented) A pharmaceutical composition according to claim 1, wherein the peptide is Gly(2)-human GLP-2.